1. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study
by Martin Schrappe, Maria Grazia Valsecchi, Claus R. Bartram, André Schrauder, Renate Panzer-Grümayer, Anja Möricke, Rosanna Parasole, Martin Zimmermann, Michael Dworzak, Barbara Buldini, Alfred Reiter, Giuseppe Basso, Thomas Klingebiel, Chiara Messina, Richard Ratei, Giovanni Cazzaniga, Rolf Koehler, Franco Locatelli, Beat W. Schäfer, Maurizio Aricò, Karl Welte, Jacques J.M. van Dongen, Helmut Gadner, Andrea Biondi, and Valentino Conter
Blood
Volume 118(8):
August 25, 2011
©2011 by American Society of Hematology

2. Overall EFS and survival of 464 T-ALL patients enrolled in the AIEOP-BFM-ALL 2000 study, and stratified by MRD.
Overall EFS and survival of 464 T-ALL patients enrolled in the AIEOP-BFM-ALL 2000 study, and stratified by MRD.
Martin Schrappe et al. Blood 2011;118:
©2011 by American Society of Hematology

3. Treatment outcome in risk groups.
Treatment outcome in risk groups. EFS (A) and cumulative incidence of relapse (B) according to PCR-based MRD classification in 464 patients.
Martin Schrappe et al. Blood 2011;118:
©2011 by American Society of Hematology

4. EFS according to immunophenotypic subgroup in 450 patients.
Martin Schrappe et al. Blood 2011;118:
©2011 by American Society of Hematology

5. Cumulative incidence of relapse in 222 T-ALL patients with negative MRD at TP2 according to MRD results at TP1.
Cumulative incidence of relapse in 222 T-ALL patients with negative MRD at TP2 according to MRD results at TP1.
Martin Schrappe et al. Blood 2011;118:
©2011 by American Society of Hematology

6. Cumulative incidence of relapse in 464 T-ALL patients by MRD levels at TP2.
Martin Schrappe et al. Blood 2011;118:
©2011 by American Society of Hematology